U. Rigney

First name
Last name
Bakhai, A., Rigney, U., Hollis, S., & Emmas, C. (2012). Co-administration of statins with cytochrome P450 3A4 inhibitors in a UK primary care population. Pharmacoepidemiol Drug Saf. http://doi.org/10.1002/pds.2308
Blak, B. T., Rigney, U., Sternhufvud, C., Davis, J., & Hammar, N. (2016). Weight change and healthcare resource use in English patients with type 2 diabetes mellitus initiating a new diabetes medication class. Int J Clin Pract. http://doi.org/10.1111/ijcp.12746
Wilding, J., Bailey, C., Rigney, U., Blak, B., Beekman, W., & Emmas, C. (2016). Glycated Hemoglobin, Body Weight and Blood Pressure in Type 2 Diabetes Patients Initiating Dapagliflozin Treatment in Primary Care: A Retrospective Study. Diabetes Ther. http://doi.org/10.1007/s13300-016-0193-8
Wilding, J., Bailey, C., Rigney, U., Blak, B., Kok, M., & Emmas, C. (2017). Dapagliflozin therapy for type 2 diabetes in primary care: Changes in HbA1c, weight and blood pressure over 2 years follow-up. Prim Care Diabetes. http://doi.org/10.1016/j.pcd.2017.04.004
J, P. H. W., Rigney, U., Blak, B. T., Nolan, S. T., Fenici, P., & Medina, J. (2019). Glycaemic, weight, and blood pressure changes associated with early versus later treatment intensification with dapagliflozin in United Kingdom primary care patients with type 2 diabetes mellitus. Diabetes Res Clin Pract. http://doi.org/10.1016/j.diabres.2019.107791
Cabrera, C., Quelen, C., Ouwens, M., Hedman, K., Rigney, U., & Quint, J. K. (2021). Evaluating a Cox marginal structural model to assess the comparative effectiveness of inhaled corticosteroids versus no inhaled corticosteroid treatment in chronic obstructive pulmonary disease. Ann Epidemiol. http://doi.org/10.1016/j.annepidem.2021.11.004